UK markets open in 30 minutes

Adverum Biotechnologies, Inc. (0HA3.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
5.90-8.10 (-57.86%)
At close: 2:30PM GMT

Adverum Biotechnologies, Inc.

800 Saginaw Drive
Redwood City, CA 94063
United States
650 656 9323

Full-time employees114

Key executives

NameTitlePayExercisedYear born
Ms. Leone D. Patterson M.B.A.Pres, CFO, Principal Financial Officer & Principal Accounting Officer874kN/A1963
Dr. Aaron OsborneChief Medical Officer695.38kN/A1974
Mr. Thomas LeungConsultant487.52kN/A1982
Dr. Laurent FischerCEO & DirectorN/AN/A1964
Ms. Angela Thedinga M.B.A., M.P.H.Chief Technology OfficerN/AN/A1982
Ms. Myesha LacyVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Peter Soparkar J.D.Chief Legal Officer & Corp. Sec.N/AN/A1971
Ms. Dena HouseVP of HRN/AN/AN/A
Mr. Christopher J. DeRespinoChief Bus. OfficerN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.

Corporate governance

Adverum Biotechnologies, Inc.’s ISS governance QualityScore as of 2 December 2020 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder rights: 9; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.